Seagen Inc.: Seagen and Genmab Present Data from Tisotumab V

-- Interim results of tisotumab vedotin plus pembrolizumab from Phase 1b/2 innovaTV 205 trial, showing 41% objective response rate in first-line patients with recurrent or metastatic cervical cancer

Related Keywords

Louisiana , United States , Japan , Tokyo , Denmark , Copenhagen , Køavn , New Jersey , Rome , Lazio , Italy , Netherlands , California , Canada , Washington , Switzerland , Seattle , American , David Freundel , Domenica Lorusso , Peggy Pinkston , Tara Castellano , Tisotumab Vedotin , David Caouette , Policlinico Gemelli , Andrew Carlsen , Product Communications , American Society Of Clinical Oncology , Twitter , Drug Administration , Seagen Inc , Nasdaq , Stage Development , Exchange Commission , Corporate Communications , European Union , European Society For Medical Oncology , Confidence Interval , American Society , Clinical Oncology , Gynaecology Oncology Unit , European Society , Medical Oncology , Safety Information , Boxed Warning , Marjorie Green , Senior Vice President , Late Stage Development , Cervical Cancer Geographical Burden , Cervical Cancer Geographical Burden Analyzer , Gynecologic Oncologist , Louisiana State University , Gynecologic Oncology , Cervical Cancer Geographical Disease Burden , Chief Executive Officer , Recommended Phase , Adverse Reactions , Fetal Toxicity , Severe Hepatic Impairment , Quarterly Report , Media Release , Annual Report , Y Shaped Genmab , Investor Relations , Vice President , Seagen , Genmab , Present , Data , Rom , Isotumab , Edotin , Tivdak , Linical , Development , Program , Dditional , Cervical , Dancer , Research , Disco , 022 , Nnual , Meeting ,